Methotrexate (Post-conception)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)3.16 [1.52, 6.54]0%5 studies32,664143not evaluable ROB
Major congenital malformations2.70 [1.21, 6.02]0%4 studies32,664143not evaluable ROB
Congenital heart defects4.80 [0.57, 40.39]37%2 studies11,02330not evaluable ROB
18 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Late intrauterine deaths (> 22 weeks)5.05 [1.21, 21.03]0%2 studies9211not evaluable ROB
Early intrauterine death (< 22 weeks)2.50 [1.43, 4.38]-1 study118188not evaluable ROB
Elective/induced termination of pregnancy7.40 [4.49, 12.18]-1 study98188not evaluable ROB
Therapeutic terminations of pregnancy4.23 [1.78, 10.04]-1 study22188not evaluable ROB